These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27058901)

  • 21. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensity matched analysis.
    Chen YP; Mao YP; Zhang WN; Chen L; Tang LL; Li WF; Liu X; Zhou GQ; Guo R; Sun Y; Kang TB; Zeng MS; Ma J
    Oncotarget; 2016 Mar; 7(12):14973-82. PubMed ID: 26942870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma.
    Qiu WZ; Peng XS; Xia HQ; Huang PY; Guo X; Cao KJ
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1563-1572. PubMed ID: 28342002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
    Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of MRI-derived masticator space involvement in IMRT-treated nasopharyngeal carcinoma patients.
    Xiao Y; Pan J; Chen Y; Lin S; Chen Y; Zong J; Fang Y; Guo Q; Chen B; Tang L
    Radiat Oncol; 2015 Sep; 10():204. PubMed ID: 26407897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma.
    Pan XB; Chen KH; Huang ST; Jiang YM; Ma JL; Liang ZG; Qu S; Li L; Chen L; Zhu XD
    Oncotarget; 2017 Sep; 8(44):78096-78104. PubMed ID: 29100451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
    Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
    JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the treatment outcomes of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma patients with parapharyngeal space extension.
    Tang LL; Chen L; Mao YP; Li WF; Sun Y; Liu LZ; Lin AH; Mai HQ; Shao JY; Li L; Ma J
    Radiother Oncol; 2015 Aug; 116(2):167-73. PubMed ID: 26316395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
    Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
    BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
    Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
    Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Value of Cavernous Sinus Invasion in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy.
    Liao JF; Ma L; Du XJ; Lan M; Guo Y; Zheng L; Xia YF; Luo W
    PLoS One; 2016; 11(1):e0146787. PubMed ID: 26824230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-treatment serum lactic dehydrogenase as a predictive indicator for distant metastasis and survival of patients with nasopharyngeal carcinoma.
    Wang J; Li L; Dong BQ; Xu YJ; Zheng YD; Sun ZW; Yang Y; Chen YY; Chen XZ; Chen M
    Oncotarget; 2016 May; 7(19):27458-67. PubMed ID: 27050275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IMRT improves local control in patients with nasopharyngeal carcinoma compared with conventional radiotherapy: propensity score-matched analysis.
    Ma Z; Umezawa R; Yamamoto T; Ishikawa Y; Takahashi N; Takeda K; Suzuki Y; Tang L; Ito K; Kadoya N; Jingu K
    Jpn J Clin Oncol; 2021 Aug; 51(9):1444-1451. PubMed ID: 34250545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
    Wang J; Zhou Z; Liang J; Feng Q; Xiao Z; Hui Z; Wang X; Lv J; Chen D; Zhang H; Ji Z; Cao J; Liu L; Jiang W; Men Y; Xu C; Dai J; Yin W; Wang L
    Oncologist; 2016 Dec; 21(12):1530-1537. PubMed ID: 27628491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Outcome and Prognostic Factors of Intensity-Modulated Radiotherapy for T4 Stage Nasopharyngeal Carcinoma.
    Luo Y; Gao Y; Yang G; Lang J
    Biomed Res Int; 2016; 2016():4398498. PubMed ID: 27195286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas.
    Du L; Zhang XX; Feng LC; Qu BL; Chen J; Yang J; Liu HX; Xu SP; Xie CB; Ma L
    BMC Cancer; 2017 Aug; 17(1):582. PubMed ID: 28851315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study.
    Lv JW; Chen YP; Zhou GQ; Tang LL; Mao YP; Li WF; Guo R; Lin AH; Ma J; Sun Y
    Oncotarget; 2016 Mar; 7(13):16806-17. PubMed ID: 26919237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.